This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the ...

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ...

Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and ...

MediPharm Labs executive management team will also host a conference call and webcast on Thursday, August 14 th, 2025 at 10:00 a.m. (Eastern time) to discuss the Company’s financial results. North ...

This data was produced from a multi-center study that enrolled 125 patients. The data demonstrates that VIVO was over 94% accurate, assisted physicians in determining workflow when used pre-procedure, ...

A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend ...

Basel, Switzerland – August 11, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient in a ...

WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the second quarter of fiscal 2025 ended June 30, 2025 in this Earnings Press Release and ...

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and developme ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...

Treatment Arms: Patients in the active treatment arm will receive two 70mg loading doses (Day 1 and Week 8) followed by two 45mg maintenance doses (Week 24 and Week 40). All patients will continue to ...